- Home
- SRAD vs CRL Comparison
SRAD vs CRL Comparison
Compare SRAD & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRAD
- CRL
- Stock Information
- Founded
- SRAD 2001
- CRL 1947
- Country
- SRAD Switzerland
- CRL United States
- Employees
- SRAD N/A
- CRL N/A
- Industry
- SRAD Computer Software: Programming Data Processing
- CRL Biotechnology: Commercial Physical & Biological Resarch
- Sector
- SRAD Technology
- CRL Health Care
- Exchange
- SRAD Nasdaq
- CRL Nasdaq
- Market Cap
- SRAD 6.8B
- CRL 6.8B
- IPO Year
- SRAD 2021
- CRL 2000
- Fundamental
- Price
- SRAD $25.40
- CRL $147.44
- Analyst Decision
- SRAD Strong Buy
- CRL Hold
- Analyst Count
- SRAD 14
- CRL 15
- Target Price
- SRAD $26.64
- CRL $186.38
- AVG Volume (30 Days)
- SRAD 1.5M
- CRL 764.6K
- Earning Date
- SRAD 08-12-2025
- CRL 08-06-2025
- Dividend Yield
- SRAD N/A
- CRL N/A
- EPS Growth
- SRAD 114.88
- CRL N/A
- EPS
- SRAD 0.20
- CRL N/A
- Revenue
- SRAD $1,245,020,536.00
- CRL $4,022,597,000.00
- Revenue This Year
- SRAD $17.66
- CRL N/A
- Revenue Next Year
- SRAD $15.21
- CRL $2.47
- P/E Ratio
- SRAD $127.78
- CRL N/A
- Revenue Growth
- SRAD 23.07
- CRL N/A
- 52 Week Low
- SRAD $10.06
- CRL $91.86
- 52 Week High
- SRAD $26.19
- CRL $254.15
- Technical
- Relative Strength Index (RSI)
- SRAD 64.37
- CRL 57.46
- Support Level
- SRAD $24.06
- CRL $143.06
- Resistance Level
- SRAD $25.44
- CRL $154.43
- Average True Range (ATR)
- SRAD 0.77
- CRL 4.61
- MACD
- SRAD 0.08
- CRL -0.18
- Stochastic Oscillator
- SRAD 72.04
- CRL 68.01
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.